See also: Generic Zofran ODT
Zofran is a brand name of ondansetron, approved by the FDA in the following formulation(s):
ZOFRAN (ondansetron hydrochloride - injectable; injection)
Manufacturer: GLAXOSMITHKLINE
Approval date: January 4, 1991
Strength(s): EQ 2MG BASE/ML [RLD][AP]
ZOFRAN (ondansetron hydrochloride - solution; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: January 24, 1997
Strength(s): EQ 4MG BASE/5ML [RLD][AA]
ZOFRAN (ondansetron hydrochloride - tablet; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: December 31, 1992
Strength(s): EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: GLAXOSMITHKLINE
Approval date: August 27, 1999
Strength(s): EQ 24MG BASE [RLD][AB]
Has a generic version of Zofran been approved?
A generic version of Zofran has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zofran and have been approved by the FDA:
ondansetron hydrochloride injectable; injection
Manufacturer: APOTEX
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: APP PHARMS
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: BAXTER HLTHCARE
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: BEDFORD
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: EMCURE PHARMS
Approval date: April 16, 2010
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: GLAND PHARMA LTD
Approval date: September 25, 2009
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: HIKMA FARMACEUTICA
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: HOSPIRA
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: HOSPIRA
Approval date: January 19, 2007
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LANNETT
Approval date: April 14, 2010
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LANNETT
Approval date: August 5, 2010
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LUITPOLD
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LUITPOLD
Approval date: November 18, 2008
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: PFIZER
Approval date: April 23, 2008
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: PLIVA HRVATSKA DOO
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: SANDOZ
Approval date: June 27, 2007
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: SPECTRUM PHARMS
Approval date: March 26, 2007
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: SUN PHARM INDS (IN)
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: TEVA
Approval date: November 22, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: WOCKHARDT
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
ondansetron hydrochloride solution; oral
Manufacturer: AMNEAL PHARMS
Approval date: January 31, 2011
Strength(s): EQ 4MG BASE/5ML [AA]
Manufacturer: APOTEX
Approval date: June 25, 2007
Strength(s): EQ 4MG BASE/5ML [AA]
Manufacturer: AUROBINDO PHARMA
Approval date: November 28, 2007
Strength(s): EQ 4MG BASE/5ML [AA]
Manufacturer: ROXANE
Approval date: December 26, 2006
Strength(s): EQ 4MG BASE/5ML [AA]
Manufacturer: SILARX
Approval date: January 27, 2011
Strength(s): EQ 4MG BASE/5ML [AA]
Manufacturer: TARO
Approval date: November 30, 2007
Strength(s): EQ 4MG BASE/5ML [AA]
ondansetron hydrochloride tablet; oral
Manufacturer: APOTEX
Approval date: June 25, 2007
Strength(s): EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: AUROBINDO PHARMA
Approval date: July 31, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: DR REDDYS LABS LTD
Approval date: December 26, 2006
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: GLENMARK GENERICS
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: MYLAN
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: NATCO PHARMA LTD
Approval date: June 25, 2007
Strength(s): EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: PAR PHARM
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: PLIVA HRVATSKA DOO
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: SANDOZ
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: SUN PHARM INDS (IN)
Approval date: June 25, 2007
Strength(s): EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: TARO
Approval date: March 28, 2011
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: TEVA
Approval date: June 25, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
Manufacturer: WEST WARD
Approval date: September 6, 2007
Strength(s): EQ 24MG BASE [AB], EQ 4MG BASE [AB], EQ 8MG BASE [AB]
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ondansetron hydrochloride injectable; injection)
Manufacturer: APOTEX INC
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: APP PHARMS
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: BAXTER HLTHCARE
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: BEDFORD LABS
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: HIKMA FARMACEUTICA
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: HOSPIRA
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LUITPOLD
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: LUITPOLD
Approval date: November 18, 2008
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: PFIZER
Approval date: April 23, 2008
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: SANDOZ
Approval date: June 27, 2007
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: SUN PHARM INDS LTD
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: TARO PHARMS IRELAND
Approval date: March 21, 2008
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: TEVA
Approval date: November 22, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Manufacturer: WOCKHARDT
Approval date: December 26, 2006
Strength(s): EQ 2MG BASE/ML [AP]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zofran. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Process and composition using ondansetron
Patent 5,344,658
Issued: September 6, 1994
Inventor(s): Collin; David T.
Assignee(s): Glaxo Group Limited
The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.Patent expiration dates:
- September 6, 2011
- March 6, 2012✓
- September 6, 2011
Oral compositions containing ondansetron
Patent 5,854,270
Issued: December 29, 1998
Inventor(s): Gambhir; Renu
Assignee(s): Glaxo Wellcome Inc.
The invention relates to a liquid composition for oral administration comprising ondansetron or a pharmaceutically acceptable derivative thereof, a sweetener and one or more pharmaceutically acceptable excipients. The sweetener comprises one or more polyhydric alcohols and the pH of the combination lies in the range 2.0 to 5.0. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5 HT) at 5 HT.sub.3 receptors are also included.Patent expiration dates:
- November 20, 2015✓✓
- May 20, 2016✓
- November 20, 2015
See also...
- Zofran Consumer Information (Drugs.com)
- Zofran Consumer Information (Wolters Kluwer)
- Zofran Solution Consumer Information (Wolters Kluwer)
- Zofran Tablets Consumer Information (Wolters Kluwer)
- Zofran Consumer Information (Cerner Multum)
- Zofran injection Consumer Information (Cerner Multum)
- Zofran Advanced Consumer Information (Micromedex)
- Zofran Oral, Oromucosal Advanced Consumer Information (Micromedex)
- Zofran AHFS DI Monographs (ASHP)
- Ondansetron Consumer Information (Drugs.com)
- Ondansetron Consumer Information (Wolters Kluwer)
- Ondansetron Orally Disintegrating Tablets Consumer Information (Wolters Kluwer)
- Ondansetron Soluble Film Consumer Information (Wolters Kluwer)
- Ondansetron Solution Consumer Information (Wolters Kluwer)
- Ondansetron Tablets Consumer Information (Wolters Kluwer)
- Ondansetron Consumer Information (Cerner Multum)
- Ondansetron injection Consumer Information (Cerner Multum)
- Ondansetron Oral, Injection, Intravenous Advanced Consumer Information (Micromedex)
- Ondansetron Oral, Oromucosal Advanced Consumer Information (Micromedex)
- Ondansetron Hydrochloride AHFS DI Monographs (ASHP)
